Metformin and the gastrointestinal tract.

McCreight LJ, Bailey CJ, Pearson ER. · 2016

Read Metformin and the gastrointestinal tract. by McCreight LJ, Bailey CJ, Pearson ER. (2016) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc4742508.txt.

Introduction

McCreight, Bailey, and Pearson make the case that the gut, not just the liver, explains how metformin works and why patients differ in their response to it. Metformin is the first-line drug for type 2 diabetes, effective and generally safe, yet up to a quarter of patients suffer gut side effects that limit dosing.

Within the intestine, the drug raises glucose uptake and lactate production, boosts the hormone GLP-1, enlarges the bile acid pool, and reshapes the microbiome. A delayed-release form controls blood sugar as well as the standard one with far less drug reaching the blood. Response and tolerance, the authors argue, are bound up with the gut.

Catalog record

CREATORMcCreight LJ, Bailey CJ, Pearson ER.
YEAR2016
COLLECTIONPAPERS
FORMATTXT
FILE SIZE48 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC4742508

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Metformin and the gastrointestinal tract By Laura J McCreight, Clifford J Bailey, Ewan R Pearson Published in: Diabetologia DOI: 10.1007/s00125-015-3844-9 ABSTRACT Abstract Metformin is an effective agent with a good safety profile that is widely used as a first-line treatment for type 2 diabetes, yet its mechanisms of action and variability in terms of efficacy and side effects remain poorly understood. Although the liver is recognised as a major site of metformin pharmacodynamics, recent evidence also implicates the gut as an important site of action. Metformin has a number of actions within the gut. It increases intestinal glucose uptake and lactate production, increases GLP-1 concentrations and the bile acid pool within the intestine, and alters the microbiome. A novel delayed-release preparation of metformin has recently been shown to improve glycaemic control to a similar extent to immediate-release metformin, but with less systemic exposure. We believe that metformin response and tolerance is intrinsically linked with the gut. This review examines the passage of metformin through the gut, and how this can affect the efficacy of metformin treatment in the individual, and contribute to the side effects associated with metformin intolerance. Keywords: Bile acids, DPP-4, GLP-1, Gut/intestine, Lactate, Metformin, Microbiome, OCT1, Review, Serotonin, Uptake INTRODUCTION Metformin—dimethylbiguanide—is an oral glucose-lowering agent. Its origins can be traced to Galega officinalis, also known as French lilac or goat’s rue [1]. In the early 20th century it was noted to lower blood glucose concentrations in animals, but it was not until the 1950s that Jean Sterne studied dimethylbiguanide and subsequently developed ‘Glucophage’ [2]. Over the last 15 years, metformin has become the first-line agent for the treatment of type 2 diabetes, as noted in several international guidelines, including the ADA-EASD guidelines [3]. Metformin has had a chequered history—it was initially eclipsed by phenformin, which was withdrawn in the late 1970s after it was discovered to be associated with lactic acidosis [4]. The lower propensity of metformin for hyperlactataemia [5] and success in several large randomised controlled clinical trials, such as the UK Prospective Diabetes Study (UKPDS) [6], confirmed its clinical benefit. It is widely recognised that metformin improves glycaemic control with a good safety profile, weight neutrality or weight loss, lack of associated hypoglycaemia, reduced cardiovascular mortality and low cost [3]. However, a large proportion of patients cannot tolerate the medication in adequate amounts because of its associated side effects. Up to 25% of patients suffer metformin-associated gastrointestinal (GI) side-effects, with approximately 5% unable to tolerate metformin at all [7]. In addition to this interindividual variation in side effects, there is variability in the efficacy of metformin. There are likely to be a number of factors to account for this variability in efficacy, for example, our group (Zhou et al) recently established that the glycaemic response to metformin is moderately heritable, i.e. due in part to genetic variation [8]. In this review we will focus on the effects of metformin on the gut and how its action within the intestine and on the intestinal enterocytes can explain at least some of the glucose-lowering effects of metformin, the increase in lactate concentrations and GI side-effects of this commonly used drug. INTESTINAL TRANSPORT OF METFORMIN Metformin is usually taken orally as the hydrochloride salt, in a tablet formulation. It exists largely as a hydrophilic cationic species at physiological pH, and has low lipid solubility, making rapid passive diffusion of metformin through cell membranes unlikely [4, 9]. Absorption of immediate-release formulations of metformin is largely confined to the small intestine, with negligible absorption in the stomach or large intestine [4, 10, 11]. In humans, intravenous administration of metformin results in rapid renal elimination, with little or no metformin detectable in the faeces [10], consistent with negligible biliary or GI secretion of metformin. However, in a mouse model of diabetes, intravenous administration of metformin does lead to accumulation of metformin in the enterocytes—most notably in the small intestine [12]. Oral bioavailability of metformin is between 50% and 60%, with approximately 30% dose recovery of unchanged metformin from faeces. Bioavailability is affected by gastric motility and may be reduced by high-fat meals [4]. The metformin concentration in the jejunum peaks at 500 μg/g, 30–300 times greater than plasma concentrations [13], highlighting the small intestine as an important site of metformin uptake. Modified-release formulations of metformin have been developed to spread the absorption of metformin along the gut and thereby reduce local concentrations of the drug, with the aim of increasing its tolerability. Metformin MR (modified-release) uses a dual polymer matrix to delay the transit and slow the release of metformin in the gut. On contact with fluid from the GI tract, the tablet swells, and the metformin is released as the polymer gradually breaks down [14]. A new metformin formulation has recently been developed, metformin DR (delayed-release), which is formulated to target the ileum via pH-dependent dissolution of the tablet. Compared with metformin IR (immediate-release) or metformin XR (extended-release), the bioavailability of metformin DR is lower, yet its glucose-lowering efficacy is similar, despite lower systemic metformin exposure [15]. This again highlights the ileum as a site of uptake and as an important site of action of metformin in lowering blood glucose. Metformin uptake is saturable and dose-dependent [10, 16], consistent with the theory that it is mostly transporter-dependent. Studies in Caco-2 cell monolayers (a cellular model of human intestinal epithelium) have shown that metformin is efficiently taken up across the apical (luminal-facing) surface of enterocytes via bidirectional transporters, but that efflux across the basolateral surface of enterocytes is limited, resulting in the accumulation of metformin in the epithelium [16], possibly accounting for the greatly increased metformin concentration seen in these cells. To account for the presence of metformin in the portal circulation, some paracellular uptake was postulated, with metformin diffusing passively. Several transporters, for which metformin is a likely substrate, have been identified e.g. organic cation transporter (OCT) 1–3, plasma membrane monoamine transporter (PMAT), multidrug and toxin extrusion protein (MATE) 1–2, serotonin transporter (SERT) and high-affinity choline transporter (CHT). OCTs are members of solute carrier family 22 (SLC22), initially described in 1994, and encoded on chromosome 6q26 [17]. OCTs are expressed in several tissues, including the intestine, liver, kidney, brain, muscle and heart. OCT1 is predominantly expressed in the liver, but plays an important role in the transfer of cations, including metformin, from the gut lumen to the interstitium [18]. Although initial reports localised OCT1 to the basolateral membrane [19], more recent reports place OCT1 on the apical surface of intestinal epithelial cells [20, 21]. OCT2 is expressed mainly in the kidney and is partly responsible for the renal excretion of metformin [18]. OCT3 is mainly expressed in the skeletal muscle, but is also expressed in the intestine. Interestingly, OCT3 is associated with metformin uptake and efflux in the salivary glands, which may account for the dysgeusia associated with metformin treatment [22]. PMAT was originally identified as a monoamine transporter from the equilibrative nucleoside transporter (ENT) family, found predominantly in the brain and central nervous system [23, 24]. It was later recognised that PMAT was polyspecific and found in many tissues throughout the body, including the intestine, where it transports metformin with comparable affinity to the OCTs [25]. PMAT is localised

Read the complete text